Literature DB >> 28276281

In vitro susceptibility and resistance phenotypes in contemporary Citrobacter isolates in a University Hospital in Crete, Greece.

Sofia Maraki1, Konstantinos Z Vardakas2,3, Viktoria-Eirini Mavromanolaki4, Margarita Kyriakidou5, George Spais5, Diamantis P Kofteridis4, George Samonis4, Matthew E Falagas2,3,6.   

Abstract

BACKGROUND: Data on Citrobacter spp. susceptibility are scarce. We sought to study the evolution in the susceptibility of 385 Citrobacter spp. at the University Hospital of Heraklion, Crete, Greece during a six-year period (2010-2015).
METHODS: Non-duplicate strains isolated from inpatients (intensive care unit, oncology, surgery, internal medicine, paediatrics) and outpatients were studied using Vitek 2. Phenotypic confirmatory tests were applied for detection of β-lactamases and aminoglycoside modifying enzymes.
RESULTS: C. freundii (172, 44.7%) and C. koseri (166, 43.1%) were the most commonly isolated species. C. braakii (34), C. amalonaticus (6), C. youngae (6) and C. sedlakii (1) were the remaining isolates. Colistin and fosfomycin were the most active antibiotics (both 99.2%) followed by carbapenems (99%) aminoglycosides (96.6-98.4%), tigecycline (96.1%), cefepime (94.8%), ciprofloxacin (94.3%), tetracycline (92.7%), trimethoprim/sulphamethoxazole (91.4%), chloramphenicol (88.1%), piperacillin/tazobactam (86.5%) and 3rd generation cephalosporins (85.7%). C. freundii were more resistant than C. koseri. Antibiotic resistance did not increase during the study period for most antibiotics. Lower susceptibility to all antibiotics was observed among multi-drug resistant (MDR) strains. AmpC was the most common resistant mechanism (10.9%); carbapenemases (1.3%) and aminoglycoside modifying enzymes (2.9%) were also detected. All AmpC producers were resistant to cephalosporins but not to carbapenems. In all but one isolates aminoglycoside resistance was accompanied by acquired β-lactamases.
CONCLUSIONS: Although Citrobacter species in general were susceptible, antibiotic susceptibility testing is required for the detection of resistant isolates.

Entities:  

Keywords:  AAC(3); AAC(6); ESBL; KPC; MBL

Mesh:

Substances:

Year:  2017        PMID: 28276281     DOI: 10.1080/23744235.2017.1297896

Source DB:  PubMed          Journal:  Infect Dis (Lond)        ISSN: 2374-4243


  3 in total

1.  Clinical and Genomic Epidemiology of Carbapenem-Nonsusceptible Citrobacter spp. at a Tertiary Health Care Center over 2 Decades.

Authors:  Ahmed Babiker; Daniel R Evans; Marissa P Griffith; Christi L McElheny; Mohamed Hassan; Lloyd G Clarke; Roberta T Mettus; Lee H Harrison; Yohei Doi; Ryan K Shields; Daria Van Tyne
Journal:  J Clin Microbiol       Date:  2020-08-24       Impact factor: 5.948

2.  The Bacteriophage vB_CbrM_HP1 Protects Crucian Carp Against Citrobacter braakii Infection.

Authors:  Chunzheng Huang; Chao Feng; Xiao Liu; Rihong Zhao; Zijing Wang; Hengyu Xi; Hongda Ou; Wenyu Han; Zhimin Guo; Jingmin Gu; Lei Zhang
Journal:  Front Vet Sci       Date:  2022-05-06

3.  Citrobacter freundii fitness during bloodstream infection.

Authors:  Mark T Anderson; Lindsay A Mitchell; Lili Zhao; Harry L T Mobley
Journal:  Sci Rep       Date:  2018-08-07       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.